Survivor: Africa Star Zohn Reports Good News

Ethan Zohn, the oh-so-cute reality star, has been public about his battle with Hodgkin’s Lymphoma during the past nine months. He had a rough beginning – the early rounds of radiation and chemo failed to put him in remission, so he decided to follow it up with a high-dose radiation treatment and a stem-cell transplant.

Now that his five weeks of radiation therapy is completed, doctors did a PET scan test to see how he responded, and the news is the best they could hope for - no active cancer cells in his body! Finally – a remission for the formerly curly-haired hearththrob.

In a People interview, he said, “"If I walked in off the street today, they would think I'm cancer free. This is the best possible news I could have gotten at this stage of my journey," he said.

"I honestly believe that all the positive healing vibes everyone has been sending me these past nine months have helped, so thank you to everyone from the bottom of my heart."
The stem cell transplant is still being planned in the next two weeks. The process is grueling and will keep him isolated for a month.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap